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STUDY QUESTION: How to select and prioritize embryos during PGD following genome-wide haplotyping?
SUMMARY ANSWER: In addition to genetic disease-specific information, the embryo selected for transfer is based on ranking criteria
including the existence of mitotic and/or meiotic aneuploidies, but not carriership of mutations causing recessive disorders.
WHAT IS KNOWN ALREADY: Embryo selection for monogenic diseases has been mainly performed using targeted disease-specific
assays. Recently, these targeted approaches are being complemented by generic genome-wide genetic analysis methods such as karyomap-
ping or haplarithmisis, which are based on genomic haplotype reconstruction of cell(s) biopsied from embryos. This provides not only infor-
mation about the inheritance of Mendelian disease alleles but also about numerical and structural chromosome anomalies and haplotypes
genome-wide. Reflections on how to use this information in the diagnostic laboratory are lacking.
STUDY DESIGN, SIZE, DURATION:We present the results of the first 101 PGD cycles (373 embryos) using haplarithmisis, performed
in the Centre for Human Genetics, UZ Leuven. The questions raised were addressed by a multidisciplinary team of clinical geneticist, fertility
specialists and ethicists.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Sixty-three couples enrolled in the genome-wide haplotyping-based PGD
program. Families presented with either inherited genetic variants causing known disorders and/or chromosomal rearrangements that could
lead to unbalanced translocations in the offspring.
MAIN RESULTS AND THE ROLE OF CHANCE: Embryos were selected based on the absence or presence of the disease allele, a tri-
somy or other chromosomal abnormality leading to known developmental disorders. In addition, morphologically normal Day 5 embryos
were prioritized for transfer based on the presence of other chromosomal imbalances and/or carrier information.
LIMITATIONS, REASONS FOR CAUTION: Some of the choices made and principles put forward are specific for cleavage-stage-based
genetic testing. The proposed guidelines are subject to continuous update based on the accumulating knowledge from the implementation of
genome-wide methods for PGD in many different centers world-wide as well as the results of ongoing scientific research.
WIDER IMPLICATIONS OF THE FINDINGS: Our embryo selection principles have a profound impact on the organization of PGD
operations and on the information that is transferred among the genetic unit, the fertility clinic and the patients. These principles are also
important for the organization of pre- and post-counseling and influence the interpretation and reporting of preimplantation genotyping
results. As novel genome-wide approaches for embryo selection are revolutionizing the field of reproductive genetics, national and inter-
national discussions to set general guidelines are warranted.
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Introduction
PGD is offered to couples that carry disease causing mutations or
chromosomal abnormalities and wish to avoid transmitting the dis-
order to their offspring (Handyside et al., 1990; Verlinsky et al., 1994).
Embryos are produced by IVF and cultured until Day 3 post-
fertilization, when one or two cells are biopsied from the cleavage-
stage embryo for genetic analysis (Harton et al., 2011). Alternatively,
PGD can be performed on polar bodies (Verlinsky et al., 1998) or fol-
lowing trophectoderm biopsy on Day 5, where 5–10 cells are
removed from the blastocyst-stage embryo (Kokkali et al., 2005).
Until recently, PGD for monogenic disorders has mainly been per-
formed via amplification of the mutated locus using (multiplex) PCR,
combined with the analysis of linked polymorphic single tandem
repeats (Renwick and Ogilvie, 2007; Spits and Sermon, 2009).
Chromosomal abnormalities, such as translocations, insertions and
inversions which are present in the parents in a balanced form, can
lead to unbalanced chromosomal constitution. The transmission of
fragments in an unbalanced form can lead to miscarriages or genetic
disorders in the child. Historically, fluorescence in situ hybridization
(FISH) was implemented for the simultaneous testing of the copy num-
ber (CN) status of multiple loci in the genome (Vanneste et al.,
2009a). To tackle the limitation in the number of loci that could be
tested in a single FISH experiment, array comparative genomic hybrid-
ization (Dimitriadou et al., 2015) and more recently massive parallel
sequencing (Deleye et al., 2015) have been introduced, allowing
genome-wide aneuploidy screening (PGS) (Harper and Harton, 2010;
Vermeesch et al., 2016). The resolution of these techniques ranges
between 1 and 4 Mb when performed on single cells (Munné, 2012).
Most recently, generic methods enabling concomitant detection of
both disease alleles as well as genome-wide numerical and structural
chromosomal anomalies have been developed and clinically implemen-
ted. Two different approaches are in use, namely karyomapping
(Natesan et al., 2014) and haplarithmisis (Zamani Esteki et al., 2015).
The process involves genome-wide single nucleotide polymorphism
(SNP) analysis of the parents and additional family members (e.g.
grandparents or a sibling), enabling the identification of informative loci
for each of the parental haplotypes across all chromosomes. By follow-
ing the inheritance of the parental haplotypes and localizing the meiotic
homologous recombination sites, the haplotype of each cell biopsied
from the embryo is reconstructed and the inheritance of Mendelian
disease variants can be inferred genome wide. The advantages of such
an approach are multifold: (i) the technique is generic and thus no
protocol optimization per family or per locus is required, given that
the analysis is performed genome-wide at high-resolution using hun-
dreds of thousands of SNPs spread across the genome; (ii) random
allelic drop-out events can be solved by using the information of neigh-
boring informative markers present at high density for each locus gen-
ome wide; (iii) meiotic homologous recombination sites can be
accurately localized; (iv) in cases of parental reciprocal translocation
carriers, it is not only possible to detect embryos carrying unbalanced
chromosomes but also to distinguish embryos that are carriers of a
balanced translocation versus chromosomally normal embryos and
(v) genome-wide CN variation can be detected, enabling the identifi-
cation of monosomies or trisomies and the distinction of meiotic from
mitotic origin of the trisomies. As a result, the selection of the embryos
to be transferred to the uterus is optimized.
Here, we present the clinical implementation of haplarithmisis and
report on 101 PGD cycles, providing insights on the incidence of mei-
otic and mitotic trisomies, uniparental disomies (UPDs), blastomeres
with multiple aneuploidies, polyploid, monosomic and segmental
imbalances as well as the frequency of blastomeres where no definitive
diagnosis can be set. Whereas most PGD testing methods thus far
focused on analyzing a single locus or a localized region of the genome,
those new methods provide a genome-wide haplotype of the embryo.
As a consequence, not only the genetic variants of interest are interro-
gated, but also other genomic variation can be analyzed. This genome-
wide view offers the potential to select embryos and prioritize embryo
transfer not only on the basis of the absence of the mutation, but also
based on the overall genetic constitution.
During the clinical implementation of haplarithmisis, several ques-
tions arose concerning embryo selection and embryo prioritization.
The questions raised were addressed by a multidisciplinary team of
clinical geneticists, fertility specialists and ethicists. Here, we present
the principles guiding embryo selection. These principles are based not
only on technical and biological, but also on ethical criteria. They
impact on the interpretation of the genotyping results, the reporting of
the results to the fertility center and the patients as well as the pre-
and post PGD-counseling.
Materials andMethods
Patient enrollment and clinical protocol
Sixty-three couples presented with either (i) inherited genetic variants
and/or (ii) chromosomal translocations (Supplementary Table SI). PGD is
not offered for alleles with low penetrance (e.g. checkpoint kinase 2
(CHEK2) mutations with only marginal increased risks for breast cancer)
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nor for genetic variants (e.g. sex determining region Y (SRY) mutations) or
‘healthy’ conditions (e.g. sex selection for non-medical reasons) (Shenfield
et al., 2003; DeWert et al., 2014).
Prospective parents are counseled by a clinical geneticist, a gynecologist-
fertility specialist and/or a counselor and, whenever appropriate, a
psychologist.
For 74.6% (n = 47) of the families enrolled, haplotypes were deduced
via the parents of one or both of the prospective parents. For the remain-
ing 16 families, a sibling was used to perform the haplotype phasing.
PGD preparation
DNA samples from the couple and other family members are analyzed
before the couple starts a PGD cycle. Genotyping is performed by SNP
arrays (Human CytoSNP12v2.1, Illumina, USA) and analyzed with Genome
Studio (Illumina) as described (Zamani Esteki et al., 2015). Genotypes from
parents, grandparents and/or siblings are not interpreted.
PGD and embryo selection
Following ICSI, embryo biopsy is performed by the removal of one
blastomere from the developing Day 3 embryo (Goossens et al., 2008).
The genome of the blastomere is then whole genome amplified (WGA)
using isothermal multiple displacement amplification (REPLI-g single cell
kit, Qiagen, Germany), quantified (Qubit, Thermo Fisher Scientific, USA)
and genotyped by SNP arrays (Human CytoSNP12v2.1, Illumina).
Subsequently, genotyping data are fed to single-cell haplotyping and
imputation of linked disease variants (siCHILD) (Zamani Esteki et al.,
2015) that reconstructs genome-wide haplotype architectures as well as
the CN and segregational origin of the haplotypes. This is possible by
employing phased parental genotypes and deciphering WGA-distorted
SNP B-allele fractions using haplarithmisis. The output of siCHILD
includes haplotyping information, via which the presence or absence of
the disease allele can be defined.
All embryos with six or more cells on Day 3 after injection are biopsied.
All biopsied embryos are further cultured until Day 5/6. Only embryos
with normal morphology on Day 5/6 are considered for embryo transfer
and/or cryopreservation.
During the first phase of the clinical implementation of the protocol
(three cycles of three families), fresh embryo transfer was performed. Test
results were obtained within 2 days and unaffected, morphologically nor-
mal embryos were transferred on Day 5. During the subsequent cycles, all
embryos developing to morulas and/or blastocysts were vitrified at
Day 5/6. Test results were obtained within 4 weeks following biopsy.
Unaffected embryos were warmed and transferred in a following single fro-
zen thawed embryo transfer cycle.
Embryo transfer management with respect
to the disease locus
For autosomal dominant disorders, selection against carriers of the muta-
tion is carried out.
For autosomal recessive disorders both non-carrier and carrier embryos
can be transferred.
For X-linked recessive (XLR) disorders both carrier (female) as well as
non-carrier (males and females) embryos can be transferred. Information
regarding the carrier status is not disclosed, unless the couple has explicitly
stated that they do not wish the transfer of carrier female embryos. In this
case, carriership information will be used for embryo selection. Carrier
status is used for embryo prioritization, as preference will be given to
non-carrier(s). For specific X-linked dominant disorders, such as Fragile X
syndrome, the selection strategy is as follows. If the mother is a carrier of a
pre-mutation, then the risk for expansion is calculated. Given that the
presence or absence of the high-risk allele can be determined in the
embryo the couple can opt for transfer of non-carriers of the disease allele
and cryopreservation of female carriers and make a final decision at a later
time point. In such cases, information regarding the sex and the carrier sta-
tus of the embryos are communicated.
For translocation carriers, both balanced carriers and non-carrier embryos
are transferred. Nevertheless, if both balanced and non-carrier embryos of
the same quality are available, preference will be given to the non-carriers.
Carrier information (autosomal and XLR or balanced translocations) is
available in the genetic lab but is not communicated with the fertility
laboratory. If wanted, this information can be communicated to the pro-
spective parents after birth.
Embryo transfer management guidelines
with respect to genetic variation not related
to the disease locus
Genetic properties which exclude embryo transfer are: (i) the embryo is a
carrier of numerical or structural abnormality in the chromosome or one of
the chromosomes carrying the disease locus; (ii) the embryo is a carrier of a
trisomy 13, 18 or 21, which might lead to Patau, Edwards and Down syn-
drome, respectively; (iii) the embryo carries multiple aneuploidies genome-
wide with gains and/or losses of several chromosomes; (iv) the embryo is
carrier of a trisomy of any chromosome of meiotic origin, which is highly likely
to be present in all blastomeres and (v) the presence of UPD of chromosome
6, 7, 11, 14 and/or 15, which are known causes of developmental disorders.
Embryo prioritization guidelines
Embryo prioritization was based on biological (i) and/or ethical (ii and iii)
criteria. (i) A numerical chromosomal abnormality, a segmental chromo-
somal abnormality or UPD not mentioned above. That chromosomally
abnormal embryos can be transferred may seem counterintuitive.
However, the mitotic error rate in cleavage embryos is higher than the
meiotic error rate (Vanneste et al., 2009c; Zamani Esteki et al., 2015) and
mosaic embryos may develop normally, implant and lead to the birth of
healthy individuals (Greco et al., 2015); (ii) an XLR mutation in a female
carrier embryo. Preference will be given to non-carrier embryos. This rank-
ing criterion is secondary to (i); (iii) a balanced translocation in the embryo.
If the embryo selection takes place in the context of balanced transloca-
tions present in (one of) the parents, a selected embryo can either be chro-
mosomally normal, or carrier of the balanced translocation transmitted
from one of the parents. Preference will be given to the chromosomally
normal embryos. This choice is secondary to the criteria (i) and (ii).
The ranking will be communicated to the embryologist, but the rationale
underlying the prioritization not. The embryologists are responsible to
choose the embryo that will be transferred, taking into account (i) the
quality of the embryo, i.e. a score based on morphological criteria, (ii) the
developmental stage of the embryo, which needs to be compatible with
the stage of the endometrial development and (iii) the genetic ranking,
based on the aforementioned criteria.
Results
First year experience
Sixty-three couples underwent 101 IVF cycles. Out of 868 metaphase II
oocytes, 668 led to the formation of a Day 1 embryo (76.9 % fertiliza-
tion rate), of which 85% (n = 568 embryos) were of adequate quality
on Day 3 to be biopsied and 48.5% (n = 324 embryos) developed into
a morphologically normal blastocyst at Day 5/6 (Fig. 1; Table I;
Supplementary Table SII).
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Embryos that underwent analysis were classified in five categories:
unaffected, affected, inconclusive, abnormal and no result (Fig. 2).
Unaffected embryos either lack the disease allele (recessive disor-
ders, dominant disorders, unbalanced translocation) or are hetero-
zygous carriers of one (recessive disorders) or two disease alleles
(balanced translocations). Affected embryos carry one (dominant)
or two (recessive) copies of the disease allele or even two different
disease alleles (combined heterozygotes for recessive disorders).
Abnormal embryos carry chromosomal aneuploidies (Fig. 3). Incon-
clusiveness is indicated when a homologous recombination site is
present closer than 150 SNPs to the locus of interest (Zamani Esteki
et al., 2015). No result can be reported in cases of whole genome
amplification failure or low SNP call rate. In such cases, following thaw-
ing of the embryo, a trophectoderm rebiopsy was performed in
two cases, leading to an ongoing clinical pregnancy in one of
them.
In total 372 out of 568 biopsied embryos have been tested, namely
324 blastocysts, 36 morulas and 12 embryos that were of adequate
quality for biopsy on Day 3, but failed to develop further (fresh cycles)
(Supplementary Table SII). Informative and conclusive results were
obtained for 92.7% (n = 345): 143 embryos (38.4%) were unaffected,
148 (39.8%) were affected and 54 (14.5%) abnormal.
Among the abnormal embryos (Supplementary Table SIII), the most
common anomaly was a haploid or polyploid profile (n = 16) followed by
aneuploidy of the chromosome of interest (n = 13), gain and/or loss of
multiple chromosomes (n = 11), aneuploidies of chromosomes 13, 18
and 21 (n = 10) as well as of other chromosomes (n = 4). Following
genetic analysis of trophectoderm samples from embryo rebiopsy
Figure 1 Selection procedure from oocyte aspiration until embryo transfer. Flow chart showing the eight consecutive selection steps that are fol-
lowed during a PGD cycle.
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(n = 14), two embryos were excluded from transfer due to the presence
of segmental aneuploidies likely present in all cells. Ranking of embryos
occurred in 22 cycles (26 embryos) (Supplementary Table SIV). Two
embryos (1 cycle) were given Ranking II because of the presence of the
balanced form of a reciprocal translocation, while diploid non-carrier
embryos (ranking I) were also available and priority was given to them.
The remaining 24 embryos were carriers of aneuploidies involving whole
chromosomes (n = 12), chromosomal segments (n = 6) or a combination
(n = 6). Interestingly, two blastomeres of different embryos carried each
one UPD, namely a maternal UPD of Chromosome 1 and a maternal
UPD of Chromosome X. Meiotic trisomies were detected in 11 embryos
(Supplementary Tables SIII–SV).
Inconclusive results were indicated in 14 (3.7%) embryos and no
result for 13 (3.5%) embryos. The latter is inflated due to one cycle,
where six out of eight tested embryos failed amplification. (Fig. 4;
Supplementary Table SII).
Embryo transfer was possible in 70 out of 101 cycles (69.3%)
(Fig. 4). In three cycles the only available unaffected embryo did not
survive the warming procedure. From the remaining 67 cycles,
embryos have already been transferred in 60 cycles. In total, 27
embryo transfers led to a clinical pregnancy, 12 of which are ongoing,
while another 15 resulted in the birth of 17 healthy babies. This gives a
pregnancy rate of 45% per finalized cycle with embryo transfer.
Thirteen embryos with aneuploidies at Day 3 (ranking II) were trans-
ferred (Supplementary Table SIV), four of which implanted. One
embryo in which the blastomere contained a partial trisomy of
chromosome four led to the birth of a healthy baby. For two embryos
with respectively a segmental deletion of the long arm of
Chromosome 22 and a monosomy of Chromosome 8 pregnancies are
ongoing. Non-invasive prenatal testing of the latter showed a normal
diploid profile. In one case (PGD105_C1; E03_Bl001), analysis of a
blastomere on Day 3 showed the presence of the non-risk (normal)
allele, but the presence of multiple monosomies genome-wide.
Nevertheless, because of the normal embryo development and
morphology at Day 5, it was decided to use this embryo for transfer.
Notably, embryo transfer led to a clinical pregnancy, which is still
ongoing.
Discussion
Since the introduction of PGD in 1990, internationally accepted
guidelines have been developed and implemented (De Wert et al.,
2014; Harper et al., 2014). Nevertheless, with the development and
introduction of novel genome-wide haplotyping technologies, new
ethical questions arise (Hens et al., 2013). The available genetic infor-
mation not only pertains the disease allele, but provides three types
of extra genetic information: (i) information about the mutation
which remained previously hidden (e.g. balanced translocation), (ii)
information about the quality of the embryonic genome, such as the
presence or absence of aneuploidies, haploidy, triploidy or UPDs in
the biopsied cell and (iii) information about the future child itself,
such as carrier status of genetic variants, based on the haplotyping
data. Importantly, the genome of the embryos is not being analyzed
for other loci, consequently, information regarding genetic variants
and mutations on the DNA sequence level is not available and will
not be communicated. Thus, informing the couple in advance regard-
ing the nature of the test is essential. Given that the genomes of
other family members (parents, grandparents and/or siblings) are
only used for haplotype phasing and are not being further analyzed,
the discussion of the consequences of potential incidental findings in
these individuals is not relevant.
Carrier identification and selection
Occasionally, the balanced translocation causes an abnormal pheno-
type and selection against it is required. Most often, both categories
of embryos (balanced carriers and non-carriers) are expected to
develop normally and knowledge of carriership is not required for
embryo selection. Nevertheless, chromosomally normal embryos
were prioritized above embryos carrying the translocation, thus
reducing the future reproductive risks of the future child. Likewise,
carriers of recessive mutations can be distinguished from non-carrier
embryos. In contrast to translocations, carrier information for reces-
sive disorders was not used for genetic selection nor for prioritiza-
tion. Most mutations causing recessive disorders are very rare, thus
the chance that a carrier child will in the future find a partner carrying
a mutation in the same gene is rather unlikely. Moreover, variants
can provide advantages under certain environment conditions in a
heterozygous state (O’Donald, 1967). Nevertheless, carriership
information can be communicated following the embryo transfer. For
XLR diseases, on the other hand, it was decided that carrier status
information can be disclosed and/or used for embryo selection,
given the 50% chance of the future individual (female) carrier to have
an affected (male) child.
.............................................................................................................................................................................................
Table I Summary of the cycles per category of indication.
AR AD XLR XLD Chromosomal Combined indications Total
Cycles 14 62 11 4 2 8 101
Oocytes 107 580 105 12 14 50 868
Fertilized 81 449 72 10 13 43 668
Biopsied 77 377 62 8 12 32 568
Blastocysts 55 213 29 6 6 15 324
Unaffected 26 86 19 2 4 6 143
AR, autosomal recessive; AD, autosomal dominant; XLR, X-linked recessive; XLD, X-linked dominant.
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Figure 2 Embryo diagnosis in relation to the mutation of interest. The disease-locus-specific analysis of two embryos from a family carrying DF408
mutation. (A) The family tree showing that both partners carry a mutated allele that has been inherited by their affected child (dark blue and blue red
haplotype). (B) single-cell haplotyping and imputation of linked disease variants (siCHILD) plots for Chromosome 7, showing that at the locus of
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Impact of genomic information on assessing
embryo quality
Selecting against embryos carrying any kind of aneuploidy will reduce
the number of embryos for transfer. In our cohort, we detected at
least one whole chromosome or segmental aneuploidy in 34.6% of the
analyzed embryos (n = 129). Nevertheless, the number of meiotic
events was limited (n = 11), which is indicative of the fact that our
group consists of young, good prognosis patients (age range = 22–41;
mean = 29.4; median = 28). Given that the aim is to help couples to
obtain offspring that do not suffer from the specific disease, it was
decided to select only against viable trisomies and trisomies of meiotic
origin. For 148 embryos, a chromosomal imbalance was detected and
in 12 embryos a transfer has been performed leading to at least four
pregnancies and one birth. A total of 30 embryos showed an abnormal
profile with multiple gains and/or losses of chromosomes upon gen-
etic analysis on Day 3, which nevertheless further developed until Day
5/6, giving rise to morphologically normal blastocysts. Importantly,
one of these embryos has been used for transfer, leading to an ongoing
clinical pregnancy. Therefore, the identification of chromosomal
abnormalities that occurred after fertilization, cannot be used as an
uncontested contraindication for embryo selection at the cleavage
stage. There is, however, accumulating evidence that the presence of
aneuploidy may reduce the overall chance for a pregnancy (Yang et al.,
2012; Forman et al., 2013; Scott et al., 2013b). This observation
prompts us to prioritize chromosomally normal embryos above
embryos with (segmental) aneuploidies.
Any embryo carrying an aneuploidy of the chromosome where the
family-specific mutation is located is currently not used for transfer, as it
could possibly interfere with the accurate interpretation of the haplo-
types regarding the locus of interest. One could argue, however, that in
case of monosomy, where the allele from the parental side carrying the
mutation is present, a safe and clear conclusion can be made. Moreover,
in case of a mitotic trisomy, the same allele will be present twice, which
would mean that the aneuploidy would not interfere with the identifica-
tion of the haplotype. Despite the aforementioned considerations, we
decided to currently exclude these embryos from transfer. No embryos
carrying a meiotic or a mitotic trisomy for either chromosome 13, 18 or
21, which may lead to a viable trisomy are used for transfer. On the
other hand, it could be argued that the trisomic cells may not survive fur-
ther during embryo development or may not even reside in the inner
cell mass that will give rise to the fetus. Moreover, the removal of one
trisomic cell from a 6 to 8-cell embryo would reduce the percentage of
trisomic cells in the embryo or even vanish them completely, leading to
a trisomy-free normal blastocyst. The question also arises how a mono-
somy of chromosome 13, 18 or 21 should be managed. For monoso-
mies, it cannot be determined whether the detected aneuploidy arose
from a mitotic or meiotic event. Given that there is a possibility that it is
a mitotic event, trisomic cells would also be present in the embryo.
Moreover, by removing one monosomic cell, the relative percentage of
trisomic cells in the embryo would have been increased enhancing the
overall trisomy risk of the future embryo. Currently, embryos showing
monosomy of chromosomes leading to viable trisomies have a low rank-
ing, but are not excluded from transfer.
Impact of detection of genome-wide
haplotypes, mutations and variants
More than 40% of individuals who are considered to be healthy have
been estimated to carry mutations in genes associated with severe
Mendelian disorders that are predicted to be damaging or are anno-
tated as disease causing (Friend and Schadt, 2014; Winand et al., 2014;
Chen et al., 2016). Consequently, at present there are still many limita-
tions in terms of analytical and clinical validity and utility of a general-
ized embryo screening. On top, high-resolution testing will also reveal
either genetic variation that is of unknown significance at present
(Kingsmore and Saunders, 2011), but which may gain significance in
the future or relevant to the general health of the future child, or even
information about their non-health related traits. In this case, this infor-
mation not only affects the decision of the parents and the specialists,
but may also have an impact on the quality of life of the future child.
Lastly, the introduction of comprehensive embryo testing allows test-
ing and selection for serious health conditions, but could prospectively
be used for the embryo selection for non-health-related traits. The
debate regarding sex selection for non-medical reasons, for example,
has been ongoing for several years already, but the range of character-
istics that can be tested for has broadened.
The basic ethical principle for embryo selection and transfer is that
the embryos may not be selected based on features that the society
considers as normal nor on characteristics that the couple may indi-
cate as desired for their future child (DeWert et al., 2014). Only clinic-
ally relevant information leading to known severe diseases can be used
for embryo selection and embryo transfer prioritization (Shenfield
et al., 2003). Hence, genetic risk factors or genetic lesions at the DNA
sequence level other than the reason of referral are currently not con-
sidered during embryo selection and prioritization.
Concluding remarks
We envision that the principles implemented in a single center could
serve as a guide for other centers adopting those novel technologies. It
is likely that some of the views presented are not shared by everyone.
Certain aspects of the choices made are likely to be culturally moti-
vated. Other choices may change with protruding insights. We envi-
sion the current process to be subject to constant evaluation and
refinement. The results of ongoing randomized control trials regarding
the clinical outcome of the implementation of genome-wide aneu-
ploidy screening will influence future selection and prioritization cri-
teria. Nevertheless, some of the principles put forward here could
potentially serve to search for a broader consensus in the community.
interest (cystic fibrosis transmembrane conductance regulator (CFTR) gene) the affected child carries two mutant alleles (dark blue and dark red);
Embryo 1 is unaffected, as it carries a normal allele inherited from the mother (light red) and a mutant allele inherited from the father (dark blue);
Embryo 2 is affected, as it carries two mutant allele (dark blue inherited from the father and dark red inherited from the mother); Embryo 3 is inconclu-
sive, as it carries one mutant allele inherited from the father (dark blue) and an inconclusive allele from the mother (light red with distance of 68 single
nucleotide polymorphisms (SNPs) from the closest recombination site).
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Some of the choices made and principles put forward are specific for
cleavage-stage-based genetic testing. At this stage, the embryo is
notoriously chromosomally unstable (Vanneste et al., 2009b). Overall,
the PGD/PGS field is gradually implementing blastocyst biopsies (Scott
et al., 2013a; Deleye et al., 2015; Goldman et al., 2016; Gui et al.,
2016), a stage when the overall genome constitution resembles more
closely the fetal fate. Nevertheless, increasing data have been showing
that mosaicism is not an exclusive characteristic of cleavage-stage
embryos, but is also prominent at the blastocyst stage (Fragouli and
Wells, 2011; Smith et al., 2015; Vera-Rodríguez et al., 2016).
However, recently the birth of healthy babies have been reported fol-
lowing the transfer of mosaic aneuploid embryos, indicating that the
presence of mosaic aneuploidies in the trophectoderm are not detri-
mental for normal embryonic and fetal development (Greco et al.,
2015). Understanding the behavior of aneuploid cells following the
blastocyst stage and understanding the potential consequences of the
Figure 3 Embryo selection based on genetic variation not related to the disease mutation. Combined information provided by haplarithm profiles
and relative copy number (CN) (logR) values show (A) a maternal trisomy 13 (T13): the logR value is elevated and the distance between the two lines
(blue and red) of the paternal haplarithm show a distance of 0.67, indicating an overrepresentation of maternal copies and a maternal monosomy 21
(M21): the logR value is diminished and the two lines of the paternal haplarithm profile fall on top of each other (distance = 0), indicating the presence
of the paternal and absence of the maternal allele, (B) a maternal uniparental disomy (UPD) of Chromosome 1 (UPD1): the logR value is neutral and
the two lines of the paternal haplarithm profile have a distance of 1, which shows the presence of the maternal and absence of the paternal alleles and
(C) a polyploidy with extra maternal copies of all chromosomes: neutral CN due to normalization genome-wide accompanied by a distortion of the
distance of the two lines of the maternal haplarithm profile for all chromosomes (distance = 0.33). For more details regarding the interpretation of hap-
larithm signatures see also Zamani Esteki et al. (2015).
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presence of (segmental) aneuploidies in the Day 5/6 embryos at the
trophectoderm will be essential to shape the decisions on embryo
selection and ranking. This warrants more research.
Finally, rapid reduction of sequencing cost over the last decade has
rendered it an attractive alternative for single-cell analysis. After having
been successfully used by several groups for CN profiling of single cells
(Zong et al., 2012; Voet et al., 2013; Binder et al., 2014; Cai et al.,
2014), efforts are lately focused on transfer of this technology to the
clinic for PGS and PGD purposes (Treff et al., 2013; Yin et al., 2013;
Wang et al., 2014; Wells et al., 2014; Deleye et al., 2015; Łukaszuk
et al., 2015; Peters et al., 2015). The guidelines introduced here, will
not only serve to address the ethical challenges due to genome-wide
haplotyping, but will remain valuable in the years to come when full
genome sequencing embryos might become a clinical reality.
Figure 4 Cycle outcome. Flow chart showing the number of cycles performed and the outcome of the cycles.
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Supplementary data are available at Human Reproduction online.
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